The Business Research Company’s report on the Head And Neck Cancer (HNC) Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
#How have key drivers contributed to the rapid growth of the head and neck cancer (hnc) market?
The increasing incidences of cigarette smoking is expected to propel the growth of the head and neck cancer (HNC) market going forward. Cigarette smoking is the act of inhaling and exhaling smoke from burning tobacco contained in cigarettes, often associated with health risks and addiction. The increasing cigarette smoking incidence is often driven by factors such as stress, social influences, aggressive marketing, and accessibility of tobacco products. Head and neck cancer drugs help mitigate the harmful effects of cigarette smoking by targeting smoking-induced molecular alterations and treating cancers linked to tobacco use, while also emphasizing the need to reduce exposure to smoking-related carcinogens for better treatment outcomes. For instance, in October 2024, according to the European Respiratory Society (ERS), a Switzerland-based non-profit organization, a study covering smoking trends among young people revealed a significant rise in smoking rates, with 22.5% of respondents smoking in 2022 compared to 40.1% in 2024. Therefore, the increased incidence of cigarette smoking is driving the growth of the head and neck cancer (HNC) market.
Access Your Free Sample of the Global Head And Neck Cancer (HNC) Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=20825&type=smp
How has the head and neck cancer (hnc) market size evolved, and what are the latest forecasts for its expansion?
The head and neck cancer (HNC) market size has grown strongly in recent years. It will grow from $2.00 billion in 2024 to $2.17 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to growth in the incidence of HPV-related cancers, an increase in smoking and alcohol consumption, rising investment in cancer research, increasing awareness and early diagnosis, and an aging population.
The head and neck cancer (HNC) market size is expected to see strong growth in the next few years. It will grow to $2.93 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to expanding healthcare infrastructure, rising patient demographics, growing geriatric population, rising healthcare expenditures, and prevalence of tobacco use and alcohol consumption. Major trends in the forecast period include immunotherapy advancements, targeted therapies, technological integration, integration of artificial intelligence (AI), and precision medicine.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=20825&type=smp
Which major companies dominate the head and neck cancer (hnc) market?
Major companies operating in the head and neck cancer (HNC) market are Pfizer Inc., Siemens Healthcare Private Limited, F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Healthcare AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Koninklijke Philips N.V., Boehringer Ingelheim, Fresenius Kabi AG, Incyte Corporation, Exelixis Inc., Astellas Pharma Inc., Rakuten Medical Inc., Merus N.V.
What trends will shape the future of the handheld marijuana vaporizer market?
Major companies operating in the head and neck cancer (HNC) market are focusing on developing innovative formulations such as immune oncology drugs, to enhance treatment efficacy, improve patient survival rates, and address unmet medical needs in managing complex and advanced-stage cancers. Immuno-oncology drugs refer to treatments that harness the body’s immune system to recognize and fight cancer cells. These therapies include checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. For instance, in November 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, launched toripalimab, an immune oncology drug for adults with a rare form of head and neck cancer that originates in the nasopharynx, the upper part of the throat. This drug is designed for treating recurrent or metastatic nasopharyngeal carcinoma. It will be marketed under the name Zytorvi. The drug has demonstrated a 48% reduction in the risk of progression or death when used in combination with standard chemotherapy (gemcitabine and cisplatin).
Which region dominates the head and neck cancer (hnc) market, and what factors contribute to its leadership?
North America was the largest region in the head and neck cancer (HNC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer (HNC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/head-and-neck-cancer-hnc-global-market-report
How is the head and neck cancer (hnc) market segmented, and which segment holds the largest share?
The head and neck cancer (HNC) market covered in this report is segmented –
1) By Type: Laryngeal Cancer, Pharyngeal Cancer, Salivary Gland Cancer, Lip And Oral Cavity Cancer, Nasopharyngeal Cancer, Other Types
2) By Treatment: Chemotherapy, Surgery, Radiation Therapy, Targeted Therapy, Other Treatments
3) By Diagnosis: Bioscopy Screening Tests, Blood Tests, Dental Diagnosis, Imaging, Endoscopy
4) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, E-commerce
5) By End User: Hospital, Specialty Clinics, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Laryngeal Cancer: Supraglottic Laryngeal Cancer, Glottic Laryngeal Cancer, Subglottic Laryngeal Cancer
2) By Pharyngeal Cancer: Oropharyngeal Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer
3) By Salivary Gland Cancer: Parotid Gland Cancer, Sublingual Gland Cancer, Submandibular Gland Cancer, Minor Salivary Gland Cancer
4) By Lip And Oral Cavity Cancer: Lip Cancer, Buccal Mucosa Cancer, Tongue Cancer, Gingival Cancer, Palate Cancer
5) By Nasopharyngeal Cancer: Early-Stage Nasopharyngeal Cancer, Advanced-Stage Nasopharyngeal Cancer
6) By Other Types: Thyroid Cancer, Esophageal Cancer, Sinonasal Cancer
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20825
What defines the structure and scope of the head and neck cancer (hnc) market?
Head and neck cancer (HNC) refers to a group of epithelial malignancies arising in the head and neck region, including the oral cavity, pharynx, larynx, nasal cavity, and salivary glands. The majority are squamous cell carcinomas, with risk factors including tobacco, alcohol, and human papillomavirus (HPV) infection.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
